| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968914 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Oct, 2016
(7 years ago) | |
| US6258795 | BTG INTL | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(9 months ago) | |
| US7776838 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(3 years from now) | |
Vistogard is owned by Btg Intl.
Vistogard contains Uridine Triacetate.
Vistogard has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Vistogard are:
- US5968914
- US6258795
Vistogard was authorised for market use on 11 December, 2015.
Vistogard is available in granule;oral dosage forms.
Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.
Drug patent challenges can be filed against Vistogard from 05 September, 2019.
The generics of Vistogard are possible to be released after 17 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-104) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 11, 2022 |
| New Product(NP) | Dec 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
VISTOGARD family patents
